Literature DB >> 20665400

Treatment of sarcoidosis.

Catherine A Lazar1, Daniel A Culver.   

Abstract

Sarcoidosis is an immune-mediated systemic syndrome of unknown etiology. The treatment of the granulomatous inflammation in sarcoidosis is thus dependent on nonspecific suppression of the immune response. Although steroid-sparing approaches have moved to front-line therapy for many other immune-mediated inflammatory diseases, corticosteroids remain the initial treatment of choice for most patients with sarcoidosis due in large part to the clinical variability and high rates of spontaneous remission. Given the heterogeneity of clinical phenotypes between patients, treatment approaches must be individualized. For patients with persistent disease, or for patients who are intolerant of systemic steroids, there are several steroid-sparing immune-modulating medications that have been effective for treating sarcoidosis. Besides immunosuppressives, we will also overview several sarcoidosis-related issues that contribute to patient-reported symptoms, a "sarcoidosis penumbra." Recognition and judicious therapy for these related issues are often key to optimizing outcomes and quality of life. Copyright Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665400     DOI: 10.1055/s-0030-1262218

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  13 in total

Review 1.  Disease Burden and Variability in Sarcoidosis.

Authors:  Alicia K Gerke; Marc A Judson; Yvette C Cozier; Daniel A Culver; Laura L Koth
Journal:  Ann Am Thorac Soc       Date:  2017-12

2.  A Prospective Review of the Results of Patients Treated and Followed up for a Diagnosis of Sarcoidosis.

Authors:  Levent Özdemir; Burcu Özdemir
Journal:  Turk Thorac J       Date:  2017-09-27

3.  18F-FDG PET/CT detects systemic involvement in sarcoidosis.

Authors:  Valentina Ambrosini; Luca Fasano; Maurizio Zompatori; Cristina Nanni; Vincenzo Allegri; Stefano Nava; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-06       Impact factor: 9.236

4.  [Therapeutic relevance of HRCT findings from a pneumological viewpoint].

Authors:  R Suchy; M Pfeifer
Journal:  Radiologe       Date:  2014-12       Impact factor: 0.635

5.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

6.  Histologic Review of Sarcoidosis in a Neck Lymph Node.

Authors:  Shannon M Welter; Javier DeLuca-Johnson; Keith Thompson
Journal:  Head Neck Pathol       Date:  2017-08-29

7.  A conceptual model of health-related quality of life in sarcoidosis.

Authors:  David E Victorson; David Cella; Heidi Grund; Marc A Judson
Journal:  Qual Life Res       Date:  2013-05-26       Impact factor: 4.147

Review 8.  Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.

Authors:  Joseph P Lynch; Jennifer Hwang; Jason Bradfield; Michael Fishbein; Kalyanam Shivkumar; Roderick Tung
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

9.  A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.

Authors:  Rémy L M Mostard; Sander M J Van Kuijk; Johny A Verschakelen; Marinus J P G van Kroonenburgh; Patty J Nelemans; Petal A H M Wijnen; Marjolein Drent
Journal:  BMC Pulm Med       Date:  2012-09-14       Impact factor: 3.317

Review 10.  Current and emerging pharmacological treatments for sarcoidosis: a review.

Authors:  Scott H Beegle; Kerry Barba; Romel Gobunsuy; Marc A Judson
Journal:  Drug Des Devel Ther       Date:  2013-04-12       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.